OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.
The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.
OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.